Al Hammadi posts SAR 108 mln net profit in 2017
31/01/2018
Argaam Exclusive
AI Summary
Content Summary: 
Loading data...
Please note that this news summary has been generated using artificial intelligence. It is recommended to review the original
sources for complete details and to verify the accuracy of the information.
View other reports
Al Hammadi Company for Development and Investment reported a net profit of SAR 107.96 million for fiscal year 2017, a 47.97 percent year-on-year (YoY) increase.
The company said the increase in net profit is attributable to a 17 percent rise in revenue due to higher numbers of patients and optimized contractual terms with customers.
Financials (M)
| Item | 2016 | 2017 | Change |
|---|---|---|---|
| Revenues | 606.24 | 708.62 | 16.9 % |
| Gross Income | 242.13 | 239.16 | (1.2 %) |
| Operating Income | 98.81 | 126.88 | 28.4 % |
| Net Income | 72.96 | 107.97 | 48.0 % |
| Average Shares | 160.00 | 160.00 | - |
| Earnings Per Share before unusual items (Riyals) | 0.46 | 0.67 | 48.0 % |
| EPS (Riyal) | 0.46 | 0.67 | 48.0 % |
The company posted a net profit of SAR 30.76 million in the fourth quarter of 2017.
Compared With The
Current Quarter Comparison (M)
| Item | Q4 2016 | Q4 2017 | Change |
|---|---|---|---|
| Revenues | 182.65 | 188.69 | 3.3 % |
| Gross Income | 73.35 | 65.08 | (11.3 %) |
| Operating Income | 18.58 | 33.93 | 82.6 % |
| Net Income | 10.48 | 30.76 | 193.4 % |
| Average Shares | 160.00 | 160.00 | - |
| Earnings Per Share before unusual items (Riyal) | 0.07 | 0.19 | 193.4 % |
| EPS (Riyal) | 0.07 | 0.19 | 193.4 % |
Profit Performance (Million)
| Period | Net Income | Change | EPS(Riyal) | Extraordinary Income/Expense | Net Profit Before Unusual Items | EPS(Riyal) |
|---|---|---|---|---|---|---|
| Q1 2017 | 27.97 | 32.3 % | 0.17 | - | 27.97 | 0.17 |
| Q2 2017 | 25.66 | 24.4 % | 0.16 | - | 25.66 | 0.16 |
| Q3 2017 | 23.59 | 13.8 % | 0.15 | - | 23.59 | 0.15 |
| Q4 2017 | 30.76 | 193.4 % | 0.19 | - | 30.76 | 0.19 |
| 2017 | 107.97 | 48.0 % | 0.67 | - | 107.97 | 0.67 |
Financial results (Million)
| Period | Revenues | Change | Gross Income | Change | Operating Income | Change |
|---|---|---|---|---|---|---|
| Q1 2017 | 180.23 | 25.0 % | 62.02 | 13.3 % | 33.61 | 26.0 % |
| Q2 2017 | 176.71 | 28.0 % | 58.16 | 1.0 % | 32.88 | 19.0 % |
| Q3 2017 | 163.01 | 15.3 % | 53.91 | (4.5 %) | 26.46 | 1.9 % |
| Q4 2017 | 188.69 | 3.3 % | 65.08 | (11.3 %) | 33.93 | 82.6 % |
| 2017 | 708.62 | 16.9 % | 239.16 | (1.2 %) | 126.88 | 28.4 % |
Profitability
| Period | Gross Margin | OIBDA Margin | Net Margin Before Unusual Items |
|---|---|---|---|
| Q1 2016 | 42.42 % | 30.79 % | 21.09 % |
| Q2 2016 | 41.32 % | 30.64 % | 18.24 % |
| Q3 2016 | 40.74 % | 29.96 % | 16.90 % |
| Q4 2016 | 39.94 % | 25.11 % | 12.04 % |
| 2016 | 39.94 % | 25.10 % | 12.03 % |
| Q1 2017 | 38.83 % | 24.74 % | 12.43 % |
| Q2 2017 | 36.71 % | 24.09 % | 12.46 % |
| Q3 2017 | 35.22 % | 23.41 % | 12.48 % |
| Q4 2017 | 33.75 % | 25.39 % | 15.24 % |
| 2017 | 33.75 % | 25.39 % | 15.24 % |
Compared With The
Per Share Data (Riyal)
| Period | Shares Outstanding (M) | EPS (Riyal) | Earnings Per Share before unusual items (Riyal) | Book Value (BV) |
|---|---|---|---|---|
| Q1 2017 | 160.00 | 0.50 | 0.50 | 8.75 |
| Q2 2017 | 160.00 | 0.53 | 0.53 | 8.89 |
| Q3 2017 | 160.00 | 0.55 | 0.55 | 9.04 |
| Q4 2017 | 160.00 | 0.67 | 0.67 | 8.67 |
Multiple Ratios (End of Period Price)
| Period | P/E | Adjusted P/E | Price/book |
|---|---|---|---|
| Q1 2017 | 61.37 | 61.37 | 3.50 |
| Q2 2017 | 58.51 | 58.51 | 3.49 |
| Q3 2017 | 47.94 | 47.94 | 2.91 |
| Q4 2017 | 41.25 | 41.25 | 3.21 |
Business Segments (Million)
Q4 2017
| Period | Healthcare services | Pharmaceutical sales revenue - Pharmacies |
|---|---|---|
| Q1 2017 | 150.74 | 29.49 |
| Q2 2017 | 147.45 | 29.26 |
| Q3 2017 | 136.70 | 26.31 |
| Q4 2017 | 155.95 | 32.73 |
Analysts Estimates (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Average | 27.89 | 30.76 | 10.29 % |
Estimates vs Actual (Million)
| Item | Profit (Expected) | Profit (Actual) | Change |
|---|---|---|---|
| Sico | 30.00 | 30.76 | 2.5 % |
| AlJazira Capital | 29.20 | 30.76 | 5.1 % |
| Alistithmar Capital | 29.20 | 30.76 | 5.1 % |
| Al Rajhi Capital | 28.00 | 30.76 | 9.0 % |
| OSOOL AND BAKHEET | 27.50 | 30.76 | 10.6 % |
| SNB Capital | 27.00 | 30.76 | 12.2 % |
| Arbah Capital | 26.20 | 30.76 | 14.8 % |
| Albilad Capital | 26.00 | 30.76 | 15.5 % |
| Current | |
| Market Cap (M Riyal) | 5,952.01 |
| Enterprise Value (EV) (M) | 5,950.85 |
| Shares Outstanding ((M)) | 160.00 |
| EPS ( Riyal) (TTM) | 2.18 |
| Book Value (BV) ( Riyal) | 12.38 |
| Par Value ( Riyal) | 10.00 |
| Recurring P/E | 20.29 |
| P/E (TTM) | 17.07 |
| Price/book | 3.01 |
| Return on Average Assets (%) (TTM) | 13.2 |
| Return on Average Equity (%) (TTM) | 18.2 |
| EV/adj EBITDA | 16.30 |
| EV/Revenues | 5.23 |
Share Price
Al Hammadi Holding (ALHAMMADI)
Follow us on
Comments {{getCommentCount()}}
Be the first to comment
{{Comments.indexOf(comment)+1}}
رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}
{{comment.DisplayName}}
{{comment.ElapsedTime}}
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.
Comments Analysis: